Caisse Des Depots ET Consignations Purchases Shares of 76,242 Edwards Lifesciences Co. (NYSE:EW)

Caisse Des Depots ET Consignations acquired a new position in Edwards Lifesciences Co. (NYSE:EW) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 76,242 shares of the medical research company’s stock, valued at approximately $5,644,000.

Other large investors have also recently made changes to their positions in the company. Crowley Wealth Management Inc. bought a new stake in Edwards Lifesciences in the fourth quarter valued at $26,000. Millstone Evans Group LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $29,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Edwards Lifesciences during the fourth quarter valued at about $30,000. FSA Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the third quarter valued at about $30,000. Finally, Roble Belko & Company Inc bought a new position in Edwards Lifesciences in the fourth quarter worth about $46,000. 79.46% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Canaccord Genuity Group upped their target price on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday, February 13th. Truist Financial restated a “hold” rating and set a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Morgan Stanley increased their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 12th. Citigroup boosted their target price on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Finally, Piper Sandler increased their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Trading Down 0.2 %

Edwards Lifesciences stock opened at $71.12 on Thursday. The business has a 50-day simple moving average of $71.45 and a two-hundred day simple moving average of $70.45. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company has a market cap of $41.81 billion, a P/E ratio of 10.20, a P/E/G ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In related news, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the sale, the director now directly owns 60,372 shares of the company’s stock, valued at approximately $4,613,628.24. This represents a 8.68 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now directly owns 23,189 shares in the company, valued at $1,594,475.64. This represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 62,553 shares of company stock valued at $4,513,064. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.